U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07839871) titled 'Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease' on Sept. 18.
Brief Summary: The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
Study Start Date: Sept. 28
Study Type: INTERVENTIONAL
Condition:
Respiratory Syncytial Virus (RSV)
Intervention:
BIOLOGICAL: RSVpreF
RSVpreF Vaccine
BIOLOGICAL: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Pfizer
Published by HT Digital Content Services with permission from He...